Determinants of response to neoadjuvant chemotherapy for esophageal cancer Using 18F-fluorodeoxiglucose positron emission tomography ( 18F-FDG-PET)

Hiroshi Miyata, Makoto Yamasaki, Tsuyoshi Takahashi, Kohei Murakami, Koji Tanaka, Kurokawa Yukinori, Kiyokazu Nakajima, Shuji Takiguchi, Eiichi Morii, Jun Hatazawa, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)


Background: 18F-FDG-PET is potentially useful for evaluating response to neoadjuvant therapy for esophageal cancer. However, the optimal 18F-FDG-PET parameter for evaluating the response to therapy and survival has not been established. This study aimed to select the best of the two parameters of fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET): decreased ratio of maximal standardized uptake (SUV max-DR) or absolute value of posttreatment SUVmax (post-SUVmax), in predicting response and survival of patients with esophageal cancer who underwent neoadjuvant chemotherapy. Methods: The study subjects were 211 consecutive patients with esophageal cancer who received neoadjuvant chemotherapy followed by surgery. 18F-FDG-PET was performed before and 2-3 weeks after completion of neoadjuvant chemotherapy in assessment with pretreatment SUVmax (pre-SUVmax), post-SUVmax and SUVmax-DR. Results: The mean SUV max decreased during neoadjuvant chemotherapy from 11.4 to 5.8, and the mean SUVmax-DR was 49.4 %. Both post-SUVmax and SUVmax-DR correlated significantly with pathological response, although neither post-SUVmax nor SUVmax-DR could distinguish pathological complete response from pathological good response. The 5-year survival rate was significantly higher in patients with SUV max-DR of >50 % than those with <50 % (56.5 vs. 39.6 %, p = 0.0137), and also significantly higher in patients with post-SUVmax of <3.5 than those with >3.5 (62.2 vs. 35.1 %, p < 0.0001). Multivariate analysis identified post-SUVmax value, but not SUV max-DR, as an independent prognostic factor in patients who underwent neoadjuvant chemotherapy. Conclusions: Post-SUVmax is more useful for predicting survival of patients with esophageal cancer who undergo neoadjuvant therapy followed by surgery, although both SUVmax-DR and post-SUVmax equally correlate with pathological response.

Original languageEnglish
Pages (from-to)575-582
Number of pages8
JournalAnnals of Surgical Oncology
Issue number2
Publication statusPublished - Feb 2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Determinants of response to neoadjuvant chemotherapy for esophageal cancer Using <sup>18</sup>F-fluorodeoxiglucose positron emission tomography ( <sup>18</sup>F-FDG-PET)'. Together they form a unique fingerprint.

Cite this